FACTS ABOUT LINSITINIB MANUFACTURER REVEALED

The LIDS trial satisfied its Most important endpoint with statistical significance for the 150mg BID dose. Linsitinib in this trial validated the security profile seen inside the prior oncology reports and importantly shown a positive protection profile on key adverse activities (AEs) of interest for your IGF-1R goal for example hearing impairment,